Contains
S:K417T
A22812C, C23248T
Earliest sequence 2022-02-19 England/ALDP-37C4703/2022
Edit by (nimimerkki cornelius. ): 70% contains ORF7a:S83L, but there's significant circulation without this mutation
Fairly large potential growth advantage at this stage."Oh interesting, convergent evolution with #540 which is a really successful BA.3 lineage with S:417T (Gamma mutation!)
Thanks (nimimerkki olias) this is a good find - especially the combination of RBD mutation and growth.
.. could you please use the advanced growth advantage against a BA.2* background? Any BA.2* will have 30% growth advantage simply because it's BA.2*. Also please filter to the country with the highest share - in this case UK. "
(Nimim. FedeQuei reminds about Orf7a::83L 14 days ago)
Remember that B.1.617.2 (Delta) carry Orf7a:V82A just near that AA. I wouldnt
dismiss that mutation as influential (for sure i agree on the designation
starting from the nuc you found) and also AY.122 had orf7a:45L and it
became the only AY. to reach top ten of more sequenced delta sub-
lineages in more than 3 continents.
But maybe, you know, it is just that i am biased versus Orf3a Orf7ab and N mutations ;)
(Nimim cornelius 6 days ago)
I just rediscovered this lineage. Was about to propose but then found it again. (Nimim) Chris R. could you have a look at designating this one? It has now also been imported into the US and France and keeps growing. It is reasonable that S:417T could help with immune escape.
(Chris R) Added new lineage BA.2.18 from #528 with 960 new sequence designations
chrisruis added this to the BA.2.18 milestone 4 days ago
Thanks @olias120676 We've added this as BA.2.18 to start on the branch with A22812C (S:N417T) which is likely the first nonsynonymous mutation in this introduction(s) into the UK
Inga kommentarer:
Skicka en kommentar